Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 4/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654917 | 0.84 | EDNRA (0.35) | POLB | |
| SCHEMBL4131558 | 0.83 | AR (0.36) | NAPRTDHODHFFAR4 | |
| SCHEMBL4023653 | 0.82 | — | — | |
| SCHEMBL3652263 | 0.82 | DHODH (0.34) | NAPRTDHODHPOLB | |
| SCHEMBL3652579 | 0.81 | PPARG (0.32) | DHODHFFAR4POLB | |
| SCHEMBL3806866 | 0.81 | GPBAR1 (0.30) | FFAR4 | |
| SCHEMBL3654415 | 0.81 | MGAM (0.33) | — | |
| SCHEMBL3654953 | 0.81 | GPBAR1 (0.33) | — | |
| SCHEMBL3649953 | 0.81 | MAOA (0.33) | POLB | |
| SCHEMBL3645629 | 0.81 | DHODH (0.36) | NAPRTDHODHFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |